title: A case report of a patient with rheumatoid arthritis complicated with Mycobacterium avium during tocilizumab treatment.
abstract: A female patient with rheumatoid arthritis (RA) suffered from Mycobacterium avium (M. avium) infection during tocilizumab treatment. Tocilizumab was discontinued and she was treated with a recommended chemotherapy, resulting in improvement of M. avium. Tocilizumab retreatment did not aggravate M. avium infection, and radiographic abnormalities improved over 1 year after cessation of the recommended therapy. Tocilizumab may be one candidate for intractable RA patients with M. avium if any biologic is required.
authors.affiliation: Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, 2-6-40 Karasugatsuji, Tennoji-ku, Osaka 543-8922, Japan. h.nakahara@mhc.west.ntt.co.jp
authors.forename: Hideko
authors.initials: H
authors.lastname: Nakahara
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Kamide
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Hamano
authors.forename: Takashi
authors.initials: T
authors.lastname: Hosokawa
authors.forename: Masayuki
authors.initials: M
authors.lastname: Nishide
authors.forename: Yu
authors.initials: Y
authors.lastname: Lin
authors.forename: Keisuke
authors.initials: K
authors.lastname: Kawamoto
authors.forename: Mie
authors.initials: M
authors.lastname: Fusama
authors.forename: Shinji
authors.initials: S
authors.lastname: Higa
authors.forename: Takashi
authors.initials: T
authors.lastname: Kuroiwa
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Igarashi
authors.forename: Taro
authors.initials: T
authors.lastname: Kuritani
authors.forename: Keiji
authors.initials: K
authors.lastname: Maeda
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D017291:Clarithromycin / Q000627:therapeutic use*; D004977:Ethambutol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009162:Mycobacterium avium; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000188:drug therapy*; D012293:Rifampin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D004977:Ethambutol; D017291:Clarithromycin; C502936:tocilizumab; D012293:Rifampin